The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome

Min Gu Park, Jeong Kyun Yeo, Dae Yeon Cho, Jin Wook Kim, Jong Wook Kim, Mi-Mi Oh, Je-Jong Kim, Du Geon Moon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Both testosterone therapy and chronic treatment with phosphodiesterase type 5 inhibitors (PDE5Is) have positive effects on the histology of penile corpora and erectile function. However, few clinical studies have evaluated the efficacy of combination therapy with both testosterone replacement and chronic PDE5Is. Aim: This study was designed to evaluate the efficacy and safety of combination treatment with long-acting injectable testosterone undecanoate (TU) and a once-daily tadalafil 5mg for erectile dysfunction with testosterone deficiency syndrome. Methods: Sixty patients were consecutively enrolled and followed for 36 weeks. Thirty patients were randomly assigned to group I and received 1,000mg of parenteral TU on day 1, followed by additional injections at weeks 6 and 18 with on-demand tadalafil 10-20mg during the 30 weeks of treatment. The remaining 30 patients received the same dose and schedule of TU as group I, and were prescribed once-daily tadalafil 5mg during 30 weeks. Main Outcome Measures: Serological tests were performed, and the International Index of Erectile Function (IIEF), Aging Males' Symptoms (AMS) questionnaires, and Global Assessment Question (GAQ) were administered to the patients. Results: Total IIEF and AMS scores were significantly improved during the 30 weeks of treatment in both groups. When IIEF scores were compared between the two groups, group II showed better symptom scores than group I at weeks 6 and 30. A similar pattern was observed when comparing AMS scores between the groups. At week 36, changes in IIEF and AMS scores that indicated worsened symptoms compared with week 30 were observed in both groups; group II showed better symptom scores than group I. On the GAQ, the ratio of patients reporting improvement in erectile function was significantly higher in group II than group I. Conclusions: The combination of long-acting injectable TU and once-daily tadalafil 5mg produced a significant improvement in erectile function. Moreover, the improvement in erectile function was well maintained, even after the cessation of treatment. Park MG, Yeo JK, Cho D-Y, Kim JW, Kim JW, Oh MM, Kim JJ, and Moon DG. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med 2015;12:966-974.

Original languageEnglish
Pages (from-to)966-974
Number of pages9
JournalJournal of Sexual Medicine
Volume12
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Fingerprint

Erectile Dysfunction
Testosterone
Injections
Phosphodiesterase 5 Inhibitors
Therapeutics
Withholding Treatment
Serologic Tests
Tadalafil
testosterone undecanoate
Histology
Appointments and Schedules
Outcome Assessment (Health Care)
Safety

Keywords

  • Erectile Dysfunction
  • Hypogonadism
  • Injectable Testosterone Undecanoate
  • Tadalafil

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Urology

Cite this

The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. / Park, Min Gu; Yeo, Jeong Kyun; Cho, Dae Yeon; Kim, Jin Wook; Kim, Jong Wook; Oh, Mi-Mi; Kim, Je-Jong; Moon, Du Geon.

In: Journal of Sexual Medicine, Vol. 12, No. 4, 01.04.2015, p. 966-974.

Research output: Contribution to journalArticle

@article{efd3e4f41355406db076bf643da4f294,
title = "The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome",
abstract = "Both testosterone therapy and chronic treatment with phosphodiesterase type 5 inhibitors (PDE5Is) have positive effects on the histology of penile corpora and erectile function. However, few clinical studies have evaluated the efficacy of combination therapy with both testosterone replacement and chronic PDE5Is. Aim: This study was designed to evaluate the efficacy and safety of combination treatment with long-acting injectable testosterone undecanoate (TU) and a once-daily tadalafil 5mg for erectile dysfunction with testosterone deficiency syndrome. Methods: Sixty patients were consecutively enrolled and followed for 36 weeks. Thirty patients were randomly assigned to group I and received 1,000mg of parenteral TU on day 1, followed by additional injections at weeks 6 and 18 with on-demand tadalafil 10-20mg during the 30 weeks of treatment. The remaining 30 patients received the same dose and schedule of TU as group I, and were prescribed once-daily tadalafil 5mg during 30 weeks. Main Outcome Measures: Serological tests were performed, and the International Index of Erectile Function (IIEF), Aging Males' Symptoms (AMS) questionnaires, and Global Assessment Question (GAQ) were administered to the patients. Results: Total IIEF and AMS scores were significantly improved during the 30 weeks of treatment in both groups. When IIEF scores were compared between the two groups, group II showed better symptom scores than group I at weeks 6 and 30. A similar pattern was observed when comparing AMS scores between the groups. At week 36, changes in IIEF and AMS scores that indicated worsened symptoms compared with week 30 were observed in both groups; group II showed better symptom scores than group I. On the GAQ, the ratio of patients reporting improvement in erectile function was significantly higher in group II than group I. Conclusions: The combination of long-acting injectable TU and once-daily tadalafil 5mg produced a significant improvement in erectile function. Moreover, the improvement in erectile function was well maintained, even after the cessation of treatment. Park MG, Yeo JK, Cho D-Y, Kim JW, Kim JW, Oh MM, Kim JJ, and Moon DG. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med 2015;12:966-974.",
keywords = "Erectile Dysfunction, Hypogonadism, Injectable Testosterone Undecanoate, Tadalafil",
author = "Park, {Min Gu} and Yeo, {Jeong Kyun} and Cho, {Dae Yeon} and Kim, {Jin Wook} and Kim, {Jong Wook} and Mi-Mi Oh and Je-Jong Kim and Moon, {Du Geon}",
year = "2015",
month = "4",
day = "1",
doi = "10.1111/jsm.12842",
language = "English",
volume = "12",
pages = "966--974",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome

AU - Park, Min Gu

AU - Yeo, Jeong Kyun

AU - Cho, Dae Yeon

AU - Kim, Jin Wook

AU - Kim, Jong Wook

AU - Oh, Mi-Mi

AU - Kim, Je-Jong

AU - Moon, Du Geon

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Both testosterone therapy and chronic treatment with phosphodiesterase type 5 inhibitors (PDE5Is) have positive effects on the histology of penile corpora and erectile function. However, few clinical studies have evaluated the efficacy of combination therapy with both testosterone replacement and chronic PDE5Is. Aim: This study was designed to evaluate the efficacy and safety of combination treatment with long-acting injectable testosterone undecanoate (TU) and a once-daily tadalafil 5mg for erectile dysfunction with testosterone deficiency syndrome. Methods: Sixty patients were consecutively enrolled and followed for 36 weeks. Thirty patients were randomly assigned to group I and received 1,000mg of parenteral TU on day 1, followed by additional injections at weeks 6 and 18 with on-demand tadalafil 10-20mg during the 30 weeks of treatment. The remaining 30 patients received the same dose and schedule of TU as group I, and were prescribed once-daily tadalafil 5mg during 30 weeks. Main Outcome Measures: Serological tests were performed, and the International Index of Erectile Function (IIEF), Aging Males' Symptoms (AMS) questionnaires, and Global Assessment Question (GAQ) were administered to the patients. Results: Total IIEF and AMS scores were significantly improved during the 30 weeks of treatment in both groups. When IIEF scores were compared between the two groups, group II showed better symptom scores than group I at weeks 6 and 30. A similar pattern was observed when comparing AMS scores between the groups. At week 36, changes in IIEF and AMS scores that indicated worsened symptoms compared with week 30 were observed in both groups; group II showed better symptom scores than group I. On the GAQ, the ratio of patients reporting improvement in erectile function was significantly higher in group II than group I. Conclusions: The combination of long-acting injectable TU and once-daily tadalafil 5mg produced a significant improvement in erectile function. Moreover, the improvement in erectile function was well maintained, even after the cessation of treatment. Park MG, Yeo JK, Cho D-Y, Kim JW, Kim JW, Oh MM, Kim JJ, and Moon DG. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med 2015;12:966-974.

AB - Both testosterone therapy and chronic treatment with phosphodiesterase type 5 inhibitors (PDE5Is) have positive effects on the histology of penile corpora and erectile function. However, few clinical studies have evaluated the efficacy of combination therapy with both testosterone replacement and chronic PDE5Is. Aim: This study was designed to evaluate the efficacy and safety of combination treatment with long-acting injectable testosterone undecanoate (TU) and a once-daily tadalafil 5mg for erectile dysfunction with testosterone deficiency syndrome. Methods: Sixty patients were consecutively enrolled and followed for 36 weeks. Thirty patients were randomly assigned to group I and received 1,000mg of parenteral TU on day 1, followed by additional injections at weeks 6 and 18 with on-demand tadalafil 10-20mg during the 30 weeks of treatment. The remaining 30 patients received the same dose and schedule of TU as group I, and were prescribed once-daily tadalafil 5mg during 30 weeks. Main Outcome Measures: Serological tests were performed, and the International Index of Erectile Function (IIEF), Aging Males' Symptoms (AMS) questionnaires, and Global Assessment Question (GAQ) were administered to the patients. Results: Total IIEF and AMS scores were significantly improved during the 30 weeks of treatment in both groups. When IIEF scores were compared between the two groups, group II showed better symptom scores than group I at weeks 6 and 30. A similar pattern was observed when comparing AMS scores between the groups. At week 36, changes in IIEF and AMS scores that indicated worsened symptoms compared with week 30 were observed in both groups; group II showed better symptom scores than group I. On the GAQ, the ratio of patients reporting improvement in erectile function was significantly higher in group II than group I. Conclusions: The combination of long-acting injectable TU and once-daily tadalafil 5mg produced a significant improvement in erectile function. Moreover, the improvement in erectile function was well maintained, even after the cessation of treatment. Park MG, Yeo JK, Cho D-Y, Kim JW, Kim JW, Oh MM, Kim JJ, and Moon DG. The efficacy of combination treatment with injectable testosterone undecanoate and daily tadalafil for erectile dysfunction with testosterone deficiency syndrome. J Sex Med 2015;12:966-974.

KW - Erectile Dysfunction

KW - Hypogonadism

KW - Injectable Testosterone Undecanoate

KW - Tadalafil

UR - http://www.scopus.com/inward/record.url?scp=84926419897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926419897&partnerID=8YFLogxK

U2 - 10.1111/jsm.12842

DO - 10.1111/jsm.12842

M3 - Article

VL - 12

SP - 966

EP - 974

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 4

ER -